Current Kidney Disease

Heart Failure, Kidney Disease

Location(s): Rovia St. Augustine (ECIR Site)

Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems. Combining balcinrenone with Dapagliflozin is experimental, which means it is not approved by any health authority such as the United States Food and Drug Administration (FDA). Dapagliflozin is an approved drug to treat patients with heart failure, chronic kidney disease and type 2 diabetes mellitus.

ASCVD Cardiovascular, Kidney Disease

Location(s): Rovia Jacksonville – University (ECIR Site), Rovia Macon (ECIR Site)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index (BMI) ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH OUTCOMES)

This study is being done to see how safe an investigational drug is and how well it will work to help people with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 and heart related and/or kidney related disease. “Investigational” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this study drug for research.

The main purpose of this study is to learn more about retatrutide (LY3437943), which is an investigational treatment for participants with Body Mass Index (BMI) of greater than or equal to 27 kg/m2 (kilogram per square meter) and heart related and/or kidney related disease.

Headquarters
3550 University Blvd South, Suite #101
Jacksonville, FL 32216

Tel: (904) 854-1354
Fax: (904) 854-1355